Pomerantz Law Firm Launches Investigation for Insmed Investors Following Disappointing Trial Results

Investor Alert: Pomerantz Law Firm Investigates Insmed Incorporated

The Pomerantz Law Firm, a respected name in the field of securities litigation, has recently announced that it is undertaking an investigation concerning claims from investors of Insmed Incorporated (NASDAQ: INSM). This initiative is primarily focused on the claims of potential misconduct surrounding the Company’s recent trials involving brensocatib, a drug aimed at treating chronic rhinosinusitis without nasal polyps (CRSsNP).

Background on Insmed and the Brensocatib Trial

On December 17, 2025, Insmed disclosed through a press release that the Phase 2b BiRCh study of brensocatib failed to meet its predetermined primary and secondary efficacy endpoints across both the 10 mg and 40 mg treatment arms. Following these disappointing results, which indicated significant challenges in advancing the drug's development, Insmed opted to cease any further development of brensocatib.

This announcement triggered a swift and severe response from the market, resulting in a notable decline of $31.91 (or 16.08%) in Insmed's stock price, closing at $166.55 on December 18, 2025. This sharp decrease raised concerns among investors about the transparency and accuracy of information released by Insmed, particularly in light of the substantial market reaction.

The Role of Pomerantz LLP

Investors who believe they have been affected by this situation are encouraged to reach out to Pomerantz LLP for a consultation. Danielle Peyton from the firm has urged those impacted to contact her through the provided channels. With extensive experience in class action lawsuits, particularly those relating to corporate and securities fraud, Pomerantz LLP is well-equipped to navigate the complexities of these claims.

Founded by the renowned Abraham L. Pomerantz, often regarded as the dean of the class action bar, the firm continues to fight for the rights of shareholders, utilizing a legacy of more than 85 years in the field. They specialize in addressing injustices caused to investors by breaches of fiduciary duty and corporate misconduct.

Next Steps for Investors

For investors in Insmed concerned about their investments, it is critical to assess the other dimensions of this situation. Investors are advised to consider their options, which may include participating in a class action lawsuit to potentially recover losses incurred due to these circumstances. Pomerantz LLP emphasizes the importance of acting promptly, as there may be deadlines that apply to these legal actions.

To proceed, investors can visit Pomerantz's official website for further information on claiming against Insmed or join the class action lawsuit that may be forming as a result of these developments.

Conclusion

As the investigation unfolds, affected investors will want to stay informed about the findings and developments from Pomerantz LLP. Given their reputation and track record in securities litigation, the outcomes of this investigation could significantly impact both the legal landscape surrounding corporate transparency and the financial recovery options for those invested in Insmed. In an era where accountability in corporate governance is paramount, cases like this reaffirm the need for diligent oversight and the role of law firms in defending investors' rights.